[1] |
ZHAO Guangqiang, XUE Tianhui, YAN Bing .
The value of the ratio of pre-operative platelet distribution width to tumor size in the prognosis of patients with non-metastatic lung adenocarcinoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(3): 317-321.
|
[2] |
MA Haijun, SHANG Chunxiang, HAN Na, LI Miao.
Effect of miR-93-5p targeting PKMYT1 on the proliferation,migration and invasion of lung adenocarcinoma A549 cells
[J]. Chinese Journal of Oncology Prevention and Treatment, 2023, 15(2): 156-162.
|
[3] |
WU Lili, ZHU Yingli, ZHUO Xiaolu, HUANG Lina, YE Dong.
Comparison of clinical efficacy of icotinib and gefitinib in the treatment of EGFR⁃mutated advanced lung adenocarcinoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2022, 14(6): 642-646.
|
[4] |
SONG Jinjing, WEI Tongtong, LIANG Kai, HUANG Zhiguang, CHEN Gang, MAO Naiquan, YANG Jie.
Expression and clinical significance of connexin 26 in lung adenocarcinoma associated fibroblasts
[J]. Chinese Journal of Oncology Prevention and Treatment, 2021, 13(2): 201-206.
|
[5] |
SU Ning, CHEN Long, Wang Lin, HE Donglei, WANG Cuiying, FENG Jun.
Surgical treament for T790M-positive lung adenocarcinoma patients with long bone metastases of extremities
[J]. Chinese Journal of Oncology Prevention and Treatment, 2019, 11(5): 398-402.
|
[6] |
Qin Yijia,Huang Bing,Lao Qifang,Zhang Lizhen.
Effect of different ventilation modes on the expression of S100A8 protein in patients undergoing pulmonary lobectomy
[J]. Chinese Journal of Oncology Prevention and Treatment, 2018, 10(6): 465-468.
|
[7] |
Liu Lingfeng,Geng Yichao,OuYang Weiwei,Ma Zhu,Li Qingsong,Li Mei, Wang Yu,Luo Daxian,Yang Wengang,Su Shengfa,He Zhixu,Lu bing.
Comparison of clinical efficacy of cisplatin combined with pemetrexed or docetaxel in stage Ⅳ lung adenocarcinoma based on propensity score matching
[J]. Chinese Journal of Oncology Prevention and Treatment, 2018, 10(4): 290-294.
|
[8] |
He Pan,Fan Ni,Chen Si,Tang Yanping,Li Kezhi,Yang Chun,Huang Xiaoqing,Cao Ji.
Expression of APOF and IGFALS in primary hepatocellular carcinoma and its clinical significance
[J]. Chinese Journal of Oncology Prevention and Treatment, 2018, 10(3): 212-215.
|
[9] |
Xu Yi,Tang Shicong, Zhou xin,Xu Xiang,Huang Yaoyuan, Wang Shoufeng,Pan Hong.
Relationship between clinicopathological features of primary human non-small cell lung cancer and their tumorigenicity in nude mice
[J]. Chinese Journal of Oncology Prevention and Treatment, 2018, 10(2): 128-132.
|
[10] |
Liang Liudan,Li Yani,Song Xiangqun,Zhou Shaozhang.
Role of the mTOR signaling pathway in the ability of 17-DMAG to overcome acquired resistance to alectinib in the H3122 lung cancer cell line positive for the EML4-ALK fusion gene
[J]. Chinese Journal of Oncology Prevention and Treatment, 2017, 9(2): 111-118.
|
[11] |
Chen Qun,Shi Qin,Xie Qiang.
Preliminary study of recombinant human endostatin (Endostar) combined with concurrent intensity-modulated radiation therapy for inoperable local advanced non-small cell lung cancer in elderly patients
[J]. Chinese Journal of Oncology Prevention and Treatment, 2017, 9(2): 142-145.
|
[12] |
Liang Xiaoqin,Wang Zhuo|,Chang Shoufeng,Zhang Xiaoling,Chen Cheng,Wang Jinsui,Su Qinjun.
ROS1 expression in pulmonary adenocarcinoma and its clinical significance
[J]. Chinese Journal of Oncology Prevention and Treatment, 2016, 8(6): 364-368.
|
[13] |
Liu Li,Qin Yuzhou,Ge Lianying.
Expression and clinical significance of hTERT in gastric cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2015, 7(6): 398-402.
|
[14] |
DONG Cui-mei,KANG Ma-fei, ZHAO Yan-yi,LI Jing,TAO Li-ying.
Correlation of methylenetetrahydrofolate reductase(MTHFR) C677T polymorphism and chemotherapy efficacy in lung adenocarcinoma
[J]. Chinese Journal of Oncology Prevention and Treatment, 2014, 6(1): 35-38.
|
[15] |
ZHU Jian-rong,WAN Xiao-lian,CUI Xiao-chuan,YU Zhen.
Detection of ERCC1 protein in lymph nodes for guiding individualized therapy in advanced non-small cell lung cancer
[J]. Chinese Journal of Oncology Prevention and Treatment, 2013, 5(4): 328-332.
|